Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVO

Novo Nordisk ADR

48.77

Jul 24 • 3:59 PM ET +0.59 (1.22%)

48.67

Aftermarket • 7:48 PM ET -0.10 (-0.21%)

Healthcare Drug Manufacturers - General Denmark Large NYSE

Jul 24, 6:40 AMNovo Nordisk seeks U.S. injunction to halt Eli Lilly weight-loss and diabetes drug ads in false-advertising lawsuit

Peers: LLY AZN MRK PFE ABBV JNJ NVS BMY SNY AMGN

| Held by: AVDE PPH WCMI PINK PID CNEQ IDVO APIE AQEC OZEM

Scroll to Statements

Index	-
Market Cap	163.77B
Enterprise Value	183.01B
Income	18.95B
Sales	50.91B
Book/sh	7.05
Cash/sh	0.99
Dividend Est.	1.79 (3.66%)
Dividend TTM	1.80 (3.69%)
Dividend Ex-Date	Mar 30, 2026
Dividend Gr. 3/5Y	26.98% 19.93%
Payout	36.87%
Employees	68794
IPO	Apr 30, 1981

P/E	11.45
Forward P/E	14.87
PEG	-
P/S	3.22
P/B	6.92
P/C	49.11
P/FCF	25.53
EV/EBITDA	6.90
EV/Sales	3.59
Quick Ratio	0.56
Current Ratio	0.79
Debt/Eq	0.72
LT Debt/Eq	0.59
Option/Short	Yes / Yes

EPS (ttm)	4.26
EPS next Y	3.28
EPS next Q	0.77
EPS this Y	-9.96%
EPS next Y	0.11%
EPS next 5Y	-0.86%
EPS past 3/5Y	26.28% 20.36%
Sales past 3/5Y	23.19% 19.21%
EPS Y/Y TTM	26.24%
Sales Y/Y TTM	16.79%
EPS Q/Q	86.54%
Sales Q/Q	37.63%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	18.04% 1.50%

Insider Own	0.00%
Insider Trans	-
Inst Own	9.81%
Inst Trans	-3.46%
ROA	24.14%
ROE	73.79%
ROIC	38.15%
Gross Margin	81.84%
Oper. Margin	45.45%
Profit Margin	37.23%
SMA20	-0.93%
SMA50	5.24%
SMA200	3.44%
Trades

Shs Outstand	3.37B
Shs Float	3.36B
Short Float	0.93%
Short Ratio	2.32
Short Interest	31.09M
52W High	71.79 -32.07%
52W Low	35.12 38.87%
Volatility	2.07% 2.15%
ATR (14)	1.26
RSI (14)	53.46
Beta	0.77
Rel Volume	0.81
Avg Volume	13.42M
Volume	10,799,115

Perf Week	-3.08%
Perf Month	2.87%
Perf Quarter	26.61%
Perf Half Y	-21.63%
Perf YTD	-4.15%
Perf Year	-31.05%
Perf 3Y	-39.82%
Perf 5Y	7.48%
Perf 10Y	75.34%
Recom	2.35
Target Price	49.77
Prev Close	48.18
Price	48.77
Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Jul-24-26 09:09AM	As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize (Barrons.com)
08:31AM	Novo Nordisk Seeks Injunction Against Eli Lilly Weight-Loss Ads (GuruFocus.com)
08:00AM	Novo Nordisk is asking a court to immediately block Eli Lilly's weight loss drug ads (Quartz)
07:56AM	Novo Nordisk seeks injunction to block Eli Lilly weight loss drug ads (Quartz)
06:50AM	Novo Nordisk Reportedly Escalates Legal Battle Against Eli Lilly Even As Analysts See LLY Leading The GLP-1 Race (Stocktwits)
06:38AM	Loading…
06:38AM	Novo Nordisk seeks court order to halt Eli Lilly weight-loss drug advertisements (InvestorsHub)
Jul-23-26 01:13PM	Lilly Targets Early 2027 Filing for Next Obesity Drug (GuruFocus.com)
08:23AM	Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing (Stocktwits)
Jul-22-26 12:01AM	Novo Nordisk Takes Rival Eli Lilly to Court Over Weight-Loss Ad Claims (The Daily Upside)
Jul-21-26 05:25PM	Novo accuses rival Eli Lilly of "deceptive" weight-loss drug ads (Axios)
02:56PM	Novo sues Lilly, claiming misleading ads in weight-loss drug battle (Reuters Videos)
12:37PM	The world is desperate for weight-loss drugs. But Big Pharma cant advertise them globally (CNN Business)
12:22PM	Novo sues Lilly after alleged misleading and false advertising campaign (Pharmaceutical Technology)
11:45AM	Pharma heavyweights clash over anti-obesity drug ads (AFP)
11:33AM	Novo Sues Lilly Over Weight-Loss Ad Claims (GuruFocus.com)
11:18AM	Loading…
11:18AM	Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims (Proactive)
10:35AM	Novo Nordisk sues Eli Lilly, accusing it of false advertising (CBS News)
10:29AM	Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising (Barrons.com)
10:01AM	Weight-loss wars: Why Novo Nordisk is suing Eli Lilly (Yahoo Finance Video)
09:50AM	Novo Nordisk sues Eli Lilly over GLP-1 advertising claims in escalating legal battle (NVO, LLY) (InvestorsHub)
09:34AM	Popular Drug Maker Slams GLP-1 Peer on False Advertising (Schaeffer's Research)
08:51AM	Novo Nordisk Lawsuit Against Eli Lilly: Wegovy Maker Alleges Misleading Zepbound, Mounjaro Ads (Stocktwits)
08:19AM	Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud (Investing.com)
08:18AM	Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications (MarketWatch)
08:05AM	Wegovy maker sues rival Eli Lilly over 'deliberately false' GLP-1 ads (USA TODAY)
07:52AM	Novo Nordisk sues Eli Lilly over misleading weight loss drug ads (Quartz)
07:50AM	Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads (Bloomberg)
07:36AM	Novo Nordisk accuses Eli Lilly of deceptive marketing in weight-loss fight (Financial Times)
Jul-20-26 09:22AM	Citi lifts Novo Nordisk target on strong GLP-1 pill launch (Proactive)
Jul-17-26 06:39AM	The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea (Yahoo Finance)
04:24AM	Loading…
04:24AM	Compounders maintain a firm grip on the GLP-1 market (Pharma Voice)
Jul-16-26 11:28AM	Novo secures European approval for oral Wegovy to extend lead over Lilly (Pharmaceutical Technology)
Jul-15-26 04:04PM	Novo Nordisk Stock Rises After Wegovy Pill Captured 89% of U.S. Prescriptions (GuruFocus.com)
04:02PM	Lilly's Obesity Pill Trails Wegovy (GuruFocus.com)
01:49PM	NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill Retail Notes LLY Is Clearly Behind Its Danish Counterpart (Stocktwits)
11:04AM	UBS says market has turned too pessimistic on AI as themes climb back up rankings (Proactive)
Jul-14-26 08:00AM	Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill (BioPharma Dive)
07:34AM	Novo Nordisk signs pact to assess semaglutide implant (Just Food)
Jul-09-26 08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
Jul-08-26 10:34AM	Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown (Proactive)
08:02AM	Leading bank backs European pharma as the cleaner alternative to the AI trade (Proactive)
07:11AM	Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant (Pharmaceutical Technology)
Jul-07-26 02:14PM	It can take as little as 5 minutes online to get prescribed a GLP-1 for weight loss. Why that's risky. (MarketWatch)
09:45AM	A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It (PR Newswire)
07:59AM	Kailera says obesity pill succeeds in late-stage trial in China (BioPharma Dive)
Jul-05-26 02:00AM	Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In? (Barrons.com)
Jul-03-26 03:10PM	Hackers claim they stole Novo Nordisk's drug and AI secrets (Quartz)
11:53AM	Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial (Quartz)
09:53AM	Microsoft Launches AI Adoption Firm (GuruFocus.com)
03:55AM	Microsoft launches Microsoft Frontier Company with $2.5bn investment (Verdict)
Jun-30-26 02:43PM	Millions of Americans can get Medicare to cover GLP-1s for weight loss starting this week. Here's how much it costs. (MarketWatch)
Jun-29-26 05:00AM	3 late-stage MASH drugs that could rival Rezdiffra (Pharma Voice)
Jun-26-26 12:47PM	How Micron aims to break through the risk cycle that has spooked investors for decades (MarketWatch)
Jun-25-26 11:26PM	HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most Voluminous Telehealth Partners (Stocktwits)
12:14AM	VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play (Stocktwits)
Jun-24-26 11:35AM	Millions of older Americans will soon have Medicare access to GLP-1s for weight loss. Here's what they need to know. (MarketWatch)
05:00AM	Recent pharma exec shake-ups signal strategic shifts (Pharma Voice)
Jun-23-26 07:46PM	VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation (Stocktwits)
Jun-22-26 09:34AM	UPS invests $48 million in cold-chain healthcare logistics (Quartz) +6.23%
08:47AM	PwC Survey Finds 70% of GLP-1 Users Cutting Snack Spending (GuruFocus.com)
Jun-19-26 02:01PM	Novo Nordisk Stock Rally as Owner Unveils $69 Million Obesity Research Push (GuruFocus.com)
01:46PM	Novo Nordisk Rises as Foundation Launches EUR 60 Million Incubator (GuruFocus.com)
08:32AM	Novo Nordisk faces limited upside from ZEUS trial as patent cliff looms, Deutsche Bank warns (Proactive)
08:08AM	Novo Bets Bigger on Obesity Research (GuruFocus.com)
07:41AM	Stocks dip after US-Iran peace talks delay; yen hovers near 40-year lows (Reuters)
04:49AM	European stocks edge higher, helped by energy and healthcare (Reuters)
Jun-18-26 01:59PM	Hims & Hers Rallies With a July FDA Decision Looming (GuruFocus.com)
06:58AM	Oral Wegovy Captures One-Third of Prescriptions as Adoption Continues to Accelerate (InvestorsHub)
Jun-17-26 04:46PM	HIMS Stock Gained Nearly 6% On Wednesday Barclays Sees Breakout Potential After Novo Partnership (Stocktwits)
03:41PM	J&J Has No Plans to Enter Obesity Drugs Market, CEO Says (Bloomberg)
03:33PM	J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030 (GuruFocus.com)
11:36AM	Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says (Investing.com)
08:08AM	Novo Nordisk hack: FulcrumSec claims $25M extortion attempt (Quartz)
Jun-16-26 02:52PM	Novo Nordisk to File Oral Wegovy in China (GuruFocus.com)
08:37AM	Novo Seeks China Approval for Wegovy Pill (GuruFocus.com)
04:49AM	Nasdaq, S&P 500 Futures Catch Breath Ahead Of First Warsh-Led Fed Decision: Why SPCX, TSLA, RKLB, BABA, NVO, HOOD, STI Are Keeping Traders Hooked (Stocktwits)
Jun-15-26 01:56PM	HIMS Stock Set To Test A Crucial Resistance Is Retail Expecting A Breakout? (Stocktwits)
Jun-14-26 04:00AM	Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they dont have college degrees, new study finds (Fortune)
Jun-12-26 10:37AM	UK gives Wegovy GLP-1 pill first European approval (Just Drinks)
07:55AM	Novo Nordisk comeback stirs as Wegovy pill wins UK approval (Pharmaceutical Technology)
Jun-11-26 02:24PM	NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News (Stocktwits)
12:22PM	Employers Rethink GLP-1 Coverage (GuruFocus.com)
11:45AM	Novo Nordisk flags patient data breach from some clinical trials in cyberattack (Reuters)
Jun-09-26 03:50PM	Novo Nordisk puts AI at the centre of its clinical strategy (Pharmaceutical Technology)
03:48PM	Novo Wegovy Pill Tops 3M Prescriptions (GuruFocus.com)
02:42PM	Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before (CNBC TV)
02:40PM	Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy (CNBC TV)
Jun-08-26 05:32PM	LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZenecas Therapies In Diabetes Trials (Stocktwits)
01:26PM	Novo Drops 3.2% As CEO Eyes Longevity And Aesthetics (GuruFocus.com)
08:30AM	Novo Nordisk's weight loss pill is hitting 3 million U.S. prescriptions and most users had never tried one before (Quartz)
08:22AM	Novo Nordisk Wegovy pill reaches 3 million U.S. prescriptions (Quartz)
07:01AM	ADA 26: Lillys dominance, Pfizers foundational drug and Roches me-too option (BioPharma Dive)
06:42AM	Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO) (InvestorsHub)
06:16AM	Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug (MarketWatch)
05:44AM	Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. (Barrons.com)
04:58AM	3 potential takeover targets in obesity (Pharma Voice)
04:44AM	Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial (MarketWatch)
Jun-07-26 07:35PM	The Wegovy pill is still dominating the GLP-1 pill market (MarketWatch)
Jun-06-26 02:53PM	Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy. (MarketWatch)
10:04AM	Pfizer targets obesity market with monthly weight-loss injection data (Investing.com)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Executive VPMr. Karsten Munk Knudsen

PresidentMr. Maziar Mike Doustdar B.A.

EVP of R&DDr. Martin Holst Lange

EVP of PeopleMs. Tania Sabroe

Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your Finviz experience